Axiron Net Sales, quarter to June 2015
Released
Released
Announcement PDF
ACRUX (ACR) - ASX ANNOUNCEMENT
24th JULY 2015
AXIRON NET SALES, QUARTER TO 30 JUNE 2015
Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of USD$32.4
million in its financial results for the quarter ended 30 June 2015.
Based on IMS data for the United States:
Market share for both new prescriptions and total prescriptions for the quarter was
consistent with recent prior quarters.
The total number of prescriptions for Axiron in the quarter ended 30 June, 2015
declined by 1% compared to the March 2015 quarter.
Axiron net sales for Acrux’s financial year ended 30 June 2015 and the prior year are shown
in the following table:
Q3 2013
Q4 2013
Q1 2014
Q2 2014
Total FY 2014
US$40.6m
US$53.9m
US$39.5m
US$47.1m
US$181.1m
Q3 2014
Q4 2014
Q1 2015
Q2 2015
Total FY 2015
US$36.3m
US$47.6m
US$39.1m
US$32.4m
US$155.4m
For the fiscal year ending 30 June 2015, Acrux earned royalties from Axiron of US$19.2
million, compared to US$22.3 million in the previous year.
Contact
Michael Kotsanis, CEO and Managing Director: 03 8379 0100
About Acrux
Acrux is an Australian drug delivery company, developing and commercialising a range of
patient-preferred, patented pharmaceutical products for global markets, using its
innovative technology to administer drugs through the skin.
The Acrux technology, used in marketed products including AXIRON®, Evamist® and
Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing
penetration enhancers, that when applied topically, deposit drug through the skin for long
acting delivery.
Acrux has three products marketed by licensees in the USA, three products approved in
Europe, and further products at earlier stages of development.
For further information on Acrux, visit www.acrux.com.au
Share your feedback
Discover